Meeting
2023 ASCO Annual Meeting
Phase 1/2 study of tiragolumab and atezolizumab in patients with relapsed or refractory SMARCB1 or SMARCA4 deficient tumors.
Authors
Mary Frances Wedekind
Pediatric Oncology Branch, NCI, NIH, Bethesda, MD
Mary Frances Wedekind , Srivandana Akshintala , Brigitte C. Widemann , Charles G. Minard , Olga Militano , David Hall , Zanette Bradley , Joel M. Reid , Joseph Gerald Pressey , Elad Sharon , Elizabeth Fox , Brenda Weigel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT05286801
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS10066)
DOI
10.1200/JCO.2023.41.16_suppl.TPS10066
Abstract #
TPS10066
Poster Bd #
372s
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
TAZNI: A phase I/II combination trial of tazemetostat with nivolumab and ipilimumab for children with INI1-negative or SMARCA4-deficient tumors.
First Author: Joanna S. Yi
Poster
2023 ASCO Annual Meeting
OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.
First Author: Dagmar Hess
Poster
2023 ASCO Annual Meeting
Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.
First Author: Jaume Capdevila
Poster
2023 ASCO Annual Meeting
Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC).
First Author: Aakash Desai